Extracted from this filing and checked against the source text.
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Mersana Therapeutics, Inc. announced a restructuring with charges of Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses. affecting all functions (approximately 55% reduction of current employee base).
- Type
- restructuring
- Charge
- Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses.
- Affected area
- all functions
- Headcount
- approximately 55% reduction of current employee base
Exact text from the filing
On May 6, 2025, Mersana Therapeutics, Inc. (the “Company”) announced the implementation of a strategic restructuring and reprioritization plan. In connection therewith, on May 5, 2025, the Company’s board of directors approved certain expense reduction measures, including the Company’s commitment to a reduction of approximately 55% of the Company’s current employee base across all functions (the “Restructuring”). The Restructuring is expected to be substantially complete by the end of the third quarter of 2025. As a result of the Restructuring, the Company estimates that it will incur approximately $4-5 million in costs resulting from cash expenditures consisting of severance and benefit payments, outplacement services and related expenses.
View on SEC.gov